FL301

FL301 is an investigational antibody-drug conjugate (ADC) being developed by Suzhou Forlong Biotechnology for the treatment of various solid tumors. It specifically targets the CD276 antigen, also known as B7-H3, which is a member of the B7 family of immune checkpoint proteins. B7-H3 is frequently overexpressed in a wide range of malignancies—including lung, prostate, and breast cancers—and is associated with tumor progression and immune evasion. FL301 is designed to utilize the specificity of a monoclonal antibody to bind to B7-H3 on the surface of cancer cells, facilitating the internal delivery of a potent cytotoxic payload. This targeted approach is intended to induce selective tumor cell death while minimizing systemic toxicity and off-target effects on healthy tissues. The asset is part of Forlong's broader pipeline focused on next-generation biologics and cytokine-based immunotherapies.